Categories: Loans

Laurus Labs Limited’s IPO to open on December 06, 2016 with Price Band of 426 – 428 per Equity Share each of Face Value of 10 each

· The Floor Price is 42.6 times of the Face Value and the Cap Price is 42.8 times of the Face Value.

· Bid can be made for a minimum of 35 Equity Shares and in multiples of 35 Equity Shares thereafter

· Discount to Eligible Employees 40 to the Offer Price

· Offer for Sale of 24,107,440 equity shares by selling shareholders

· Fresh issue of equity share aggregating up to Rs. 3,000 million

· Bid/Offer Opening Date – December 06, 2016 and Bid/Offer Closing Date – December 08, 2016

Hyderabad, December 06, 2016: Hyderabad based Laurus Labs Limited, a research and development driven pharmaceutical company (the “Company”) will launchits Initial Public Offering (“IPO” or the “Offer”) which is scheduled to open on December 06, 2016 and close on December 08, 2016, with a price band of INR426– INR428 per equity shares of face value of Rs. 10 each of the Company (the “EquityShares”). The Company may, in consultation with the Book Running Lead Managers (the “BRLMs”), consider participation by Anchor Investors in accordance with the Securities and Exchange Board of India (Issue of Capital and disclosure Requirements) Regulations, 2009 (“SEBI ICDR Regulations”). The Anchor Investors shall Bid during the Anchor Investor Bid/Offer Period, i.e., one Working Day prior to the Bid/Offer Opening Date.

The Offer consists of fresh issue of Equity Shares aggregating up to Rs. 3,000 million (“Fresh Issue”) and an offer for sale of 24,107,440Equity Shares (“Offer for Sale”) by the selling shareholders namely Aptuit (Asia) Private Limited, Bluewater Investment Ltd, FIL Capital Management (Mauritius) Limited and Fidelity India Principals (acting through its trustee FIL Capital Advisors) (the “Selling Shareholders”).The Offer includes a reservation of up to such number of Equity Shares aggregating up to Rs. 125 million, for subscription by eligible employees (as defined in the RHP) not exceeding 5% of the Company’sPost-Offer paid up Equity Share capital (the “Employee Reservation Portion”). The Offer less the Employee Reservation Portion is hereinafter referred to as the “NetOffer”.

The Company will not receive any proceeds from the Offer for Sale and all proceeds from the Offer for Sale will go to the Selling Shareholders. The Company proposes to use the net proceeds from the Fresh Issue towards pre-payment of term loans and general corporate purposes.

The Offer is being made through the Book Building Process,in terms of of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), andin accordance with Regulation 26(1) of the SEBI ICDR Regulations, wherein 50% of the Net Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”),provided thatour Company may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors (“Anchor Investor Portion”) at the Anchor Investor Allocation Price, on a discretionary basis, out of which at least one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Offer Price, in accordance with the SEBI ICDR Regulations.

5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price.

Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price such that, subject to availability of Equity Shares, each Retail Individual Bidder shall be Allotted not less than the minimum Bid Lot, and the remaining Equity Shares, if available, shall be Allotted to all Retail Individual Bidders on a proportionate basis. Further, such number of equity shares aggregating up to Rs.125 million shall be available for allocation on a proportionate basis to Eligible Employees, subject to Valid Bids being received from them at or above the offer price after the Employee Discount. All potential investors, other than Anchor Investors, are required to mandatorily utilise the Applications Supported by Blocked Amount (“ASBA”) process by providing the details of their respective bank accounts in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks (“SCSBs”) to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see the section titled “Offer Procedure” on page 530 of the RHP.

Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Jefferies India Private Limited and SBI Capital Markets Limited are the BRLMsto the Offer. The Registrar to the Offer is Karvy Computershare Private Limited.

The Equity Shares of the Company are proposed to be listed on the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”)

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

2 days ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

2 days ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

3 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

3 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

4 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

4 days ago